Search Icon


Drug Information

Product NDC: 0469-5020

Proprietary Name: Myrbetriq

Non Proprietary Name: mirabegron

Active Ingredient(s):
  • 8 mg/mL MIRABEGRON

Administration Route(s): ORAL


Pharmacy Class(es):
  • Adrenergic beta3-Agonists [MoA];
  • Cytochrome P450 2D6 Inhibitors [MoA];
  • Cytochrome P450 3A Inhibitors [MoA];
  • P-Glycoprotein Inhibitors [MoA];
  • beta3-Adrenergic Agonist [EPC]

Labeler Information

Labeler Name: Astellas Pharma US, Inc.
FDA Application Number: NDA213801
Marketing Category: NDA
Start Marketing Date:3/25/2021

Package Information

No. Package Code Package Description Billing Unit
10469-5020-991 BOTTLE in 1 CARTON (0469-5020-99) > 100 mL in 1 BOTTLEML

NDC Record

Field Name Field Value Definition
PRODUCT NDC0469-5020The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEMyrbetriqThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEmirabegronThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMEGRANULE, FOR SUSPENSION, EXTENDED RELEASEThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE3/25/2021This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMENDAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at under Structured Product Labeling Resources.
APPLICATION NUMBERNDA213801This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMEAstellas Pharma US, Inc.Name of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEMIRABEGRONAn active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
PHARM CLASSESAdrenergic beta3-Agonists [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], beta3-Adrenergic Agonist [EPC] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 11/10/2022